CHNA
Loncar China BioPharma ETF
CHNA
CHNA
Delisted
CHNA was delisted on the 20th of October, 2023.
5 hedge funds and large institutions have $574K invested in Loncar China BioPharma ETF in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Jane Street
New York
|
+$55K |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$16.1K |
| 2 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
-$2.65K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $560K | +$55K | +2,928 | +11% |
|
|
BBPWM
2
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $5.78K | -$2.65K | -141 | -31% |
|
|
3
UBS Group
Zurich,
Switzerland
| $4.73K | -$16.1K | -859 | -77% |
|
4
Morgan Stanley
New York
| $3.53K | – | – | – |
|